The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: PRospective Prostate biOmarker Study
Official Title: PRospective Prostate biOmarker Study (PROPOSe)
Study ID: NCT03565289
Brief Summary: • Correlation of a glycoprotein panel with prostate biopsy outcome and PCa aggressiveness
Detailed Description: The main objective of this study is to correlate a glycoprotein panel with prostate biopsy outcome, i.e. distinguishing PCa from benign prostatic conditions as well as high-grade cancer. The quantities of the two protein analytes cathepsin D (CTSD) and thrombospondin 1 (THBS1) are measured in human serum samples. In combination with percent free PSA (%fPSA), the results are correlated with prostate biopsy outcome. The potential future benefit of using this glycoprotein panel is to validate positive tPSA tests in men with negative digital rectal examination (DRE) and enlarged prostates to reduce the need for undergoing a biopsy, thereby reducing unnecessary biopsies and potentially predicting high-grade disease.
Minimum Age: 45 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Ordensklinikum Linz, Linz, Oberösterreich, Austria
Medizinische Universität Innsbruck, Innsbruck, , Austria
Rigshospitalet, Copenhagen, , Denmark
Universitätsklinikum Münster, Münster, NRW, Germany
Helios Klinikum Bad Saarow, Bad Saarow, , Germany
Malteser Krankenhaus Bonn/Rhein-Sieg, Bonn, , Germany
Städtisches Klinikum Braunschweig gGmbH, Braunschweig, , Germany
Universitätsklinikum Frankfurt, Frankfurt, , Germany
Martini Klinik am UKE GmbH, Hamburg, , Germany
Marien-Hospital Herne, Herne, , Germany
Daikonie Klinikum Stuttgart, Stuttgart, , Germany
Name: Thomas Steuber, Prof. Dr.
Affiliation: Martiniklinik am UKE gGmbH
Role: PRINCIPAL_INVESTIGATOR